SUTRO BIOPHARMA, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $166.4M | $252.0M | $180.4M | $137.2M | $104.4M | $77.0M | $65.6M |
| SG&A Expense | — | $41.0M | $48.5M | $62.6M | $59.5M | $56.0M | $36.8M | $32.6M |
| Operating Income | — | $-158.4M | $-238.5M | $-89.3M | $-128.9M | $-98.5M | $-71.1M | $-55.5M |
| Operating Margin | — | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | -129.8% |
| Interest Expense | — | — | — | $1.3M | $2.4M | $2.6M | $2.3M | $1.1M |
| Pretax Income | — | $-191.2M | $-225.1M | $-88.6M | $-116.7M | $-105.5M | $-32.0M | — |
| Income Tax Expense | — | $-93.0K | $2.4M | $18.2M | $2.5M | $0 | $103.0K | $0 |
| Net Income | — | $-191.1M | $-227.5M | $-106.8M | $-119.2M | $-105.5M | $-32.1M | $-119.2M |
| Net Margin | — | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -278.9% |
| EPS (Basic) | — | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | $-2.43 |
| EPS (Diluted) | — | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | $-2.43 |
| Shares Outstanding (Basic) | 16.6M | 8.5M | 7.7M | 60.2M | 50.7M | 46.1M | 32.6M | 23.1M |
| Shares Outstanding (Diluted) | 16.6M | 8.5M | 7.7M | 60.2M | 50.7M | 46.1M | 32.6M | 23.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |